Outsourcing-Pharma RSS

People on the move

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Thu, 02 Feb 2012 13:20:38 +0100

Outsourcing-Pharma presents its weekly round-up of the latest career changes within the pharmaceutical industry, including news from Icon, AbelsonTaylor and Chiltern.

CMO news roundup – Foster, Excella, Catalent and RohnerChem

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Thu, 02 Feb 2012 11:26:45 +0100

A round-up of news in the contract manufacturing space, with developments at Foster Delivery Sciences, Excella, Catalent and RohnerChem.

Almac challenges "one-size-fits-all" DNA analysis with new custom-fit service

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Thu, 02 Feb 2012 13:06:03 +0100

Almac says its first leap into Next Generation Sequencing (NGS) data analysis services is a much needed-change from the industry’s current “one-size-fits-all” offering.

Ipsen to take writedown after Lonza warning letter hits supply

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Thu, 02 Feb 2012 13:01:29 +0100

Ipsen may take a writedown up to €180m after FDA action against its API CMO, Lonza, created supply uncertainties.

Marken forms tech team as cold chain market heats up

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Thu, 02 Feb 2012 12:21:58 +0100

Trial logistics firm Marken says new expert development team will create ‘industry changing,’ cold chain technologies.

Clinart MENA rebrands to meet demand for Middle East trials

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Thu, 02 Feb 2012 14:39:52 +0100

Clinart MENA has hired a new CEO and rebranded to benefit from rising interest in conducting trials in the Middle East.

Absorption Systems sees potential in ocular testing services

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Wed, 01 Feb 2012 12:57:55 +0100

Preclinical CRO Absorption Systems is adding new technologies and capabilities for the analysis of ocular drugs at its lab in San Diego, US.

Encap lands long-term manufacturing contract

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Wed, 01 Feb 2012 12:33:29 +0100

Encap Drug Delivery has won a contract manufacturing deal for a European licensed liquid-filled capsule product after the owner parted from its current CMO.

CMO Cytovance adds 1,000L bioreactor for trial supplies

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Wed, 01 Feb 2012 12:24:10 +0100

Cytovance Biologics has added a 1,000L bioreactor at its Oklahoma site to support scale-up as clients move through clinical trials.

Big pharma shifting trial focus to US at expense of Asia; Parexel

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Wed, 01 Feb 2012 10:41:32 +0100

Strategic clients increasingly want to outsource trials to the ‘old world’ of the US and Europe at the expense of Asia, Parexel said.

TNT offering temperature-controlled logistics services

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Tue, 31 Jan 2012 12:37:50 +0100

TNT Express is now offering temperature-controlled logistics services to support global distribution of biologics.

Avoca invites CROs to join Pharma sponsors in Quality management debate

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Tue, 31 Jan 2012 11:16:45 +0100

Sponsors want CROs to join the debate on quality management in clinical research says the Avoca Group, which has invited contractors to sign up to its recently established industry consortium.

Dishman considers future of Chinese API plant

Nathan.GRAY@wrbm.com (Nathan GRAY) — Tue, 31 Jan 2012 12:55:23 +0100

Ingredient maker Dishman Pharmaceuticals has confirmed that it may offload its Chinese API (active pharmaceutical ingredients) factory.

Parexel posts soaring sales and backlog but costs cut profits

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Tue, 31 Jan 2012 11:33:56 +0100

Parexel posted double-digit revenue growth and record backlog in its second quarter, but rising costs drove down profits.

Russian trial approvals up in 2011, but reviews still slow says ACTO

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Mon, 30 Jan 2012 12:31:38 +0100

Russia’s trial sector has largely recovered from the ‘crisis’ created by revision of approval system in 2010, but regulators are still taking too long to OK studies says industry group ACTO.

Lpath suspends dosing after FDA warns of CMO failings

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Mon, 30 Jan 2012 12:47:15 +0100

Lpath has suspending dosing in its iSONEP clinical trials after learning the CMO handling fill and finish has cGMP failings.

HUYA Bioscience wants stronger bonds with international drugmakers

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Mon, 30 Jan 2012 14:13:39 +0100

HUYA Bioscience says it will strengthen bonds between Chinese drug innovators and worldwide developers and through its new partnership with the Tianjin Institute of Pharmaceutical Research (TIPR).

Covance plans cuts to early dev unit if sales are flat in 2012

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Mon, 30 Jan 2012 11:11:04 +0100

Covance could cut early development capacity if the unit posts flat sales in the coming fiscal year, its CEO said.

People on the move: outsourcing jobs

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Thu, 26 Jan 2012 10:47:32 +0100

Outsourcing-Pharma presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Patheon, Wolfe Laboratories, and Premier Research.

Covance shocks analysts with two year IT investment plan

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Thu, 26 Jan 2012 11:18:33 +0100

Covance is accelerating IT investment faster and for longer than expected, resulting in 2012 guidance that met analysts’ “worst-case fears”.